31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease.

31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Abstract Text:

Adrian K P Lim,Nayna Patel,Gavin Hamilton,Kailash Mylvahan,Yu-Ting Kuo,Robert D Goldin,Simon D Taylor-Robinson,

OBJECTIVE: An increase in the ratio of phosphomonoester (PME) to phosphodiester (PDE) during 31P MR spectroscopy of the liver has been observed with increasing severity of hepatitis C-related liver disease. The purpose of this study was to investigate the utility of 31P MR spectroscopy as a biomarker of response to interferon and ribavirin treatment. SUBJECTS AND METHODS: Forty-seven patients with biopsy-proven hepatitis C undergoing viral eradication treatment with interferon and ribavirin underwent hepatic 31P MR spectroscopy at 1.5 T (voxel size, 70 x 70 x 70 mm; TR, 10,000; number of signals averaged, 48). All underwent baseline imaging before treatment and repeated imaging at 6-month intervals after the start of treatment. RESULTS: All patients underwent follow-up imaging 6 months after the start of treatment; 25 patients, 12 months; and 10 patients, 18 months after the start of treatment. According to the Ishak histologic scoring system, nine patients had mild hepatitis; 30 patients, moderate to severe hepatitis; and eight patients, cirrhosis. Thirty-two patients responded to antiviral treatment. Among these patients, 25 had a decrease in PME/PDE ratio on follow-up imaging. Among responders the mean baseline PME/PDE ratio decreased from 0.27 +/- 0.02 (standard error) to 0.16 +/- 0.01 after treatment (paired Student's t test, p < 0.001). Among the 15 virologic nonresponders, the ratios were similar in six patients; six other patients had an increase on follow-up imaging. In the latter nonresponder group, the mean baseline PME/PDE ratio was 0.21 +/- 0.03 compared with 0.31 +/- 0.08 after treatment (paired Student's t test, p =0.24). CONCLUSION: The in vivo hepatic PME/PDE ratio decreased in patients with hepatitis C who responded to antiviral treatment and remained similar or increased in patients without a virologic response. These results suggest that PME and PDE can be used as biomarkers in a noninvasive test of response to treatment.

31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Publishing Authors By Initials

AK Lim,N Patel,G Hamilton,K Mylvahan,YT Kuo,RD Goldin,SD Taylor-Robinson,

For similar complex mixtures: biological products: vaccines: viral vaccines: viral hepatitis vaccines research abstracts see: complex mixtures: biological products: vaccines: viral vaccines: viral hepatitis vaccines research

PUBMED ID PMID:

MEDLINE DATE:

31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: AJR. American journal of roentgenology

VOLUME: 189

Page Numbers: 819-23

Journal Abbreviation:

ISSN: 1546-3141

DAY: 15

MONTH: Oct

YEAR: 2007

31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7708173

31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Keywords Mesh Terms:

KEYWORDS: Viral Hepatitis Vaccines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: 31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Information

Substance Name: Viral Hepatitis Vaccines

Registry Number: 0

Grant and Affiliation Information for 31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease.

AFFILIATION: Department of Imaging Sciences, Faculty of Medicine, Imperial College London, Robert Steiner MRI Unit, MRC Clinical Sciences Centre, Hammersmith Hospital, Du Cane Rd., London W12 0HS, United Kingdom. a.lim@ic.ac.uk

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: AJR Am J Roentgenol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease Related Publications

• 31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease.
• A model of development of acquired immunity to malaria in humans living under endemic conditions.
• An enzyme-linked immunosorbent assay (ELISA) for the detection of chlamydial antibody in duck sera.
• Cerebral immune activation in chronic hepatitis C infection: A magnetic resonance spectroscopy study.
• Cholangiocarcinoma and its management.
• David Arthur John Tyrrell CBE: 19 June 1925 - 2 May 2005.
• Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women.
• Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.
• Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis.
• Hormones in bacterial vaginosis.
• Letter: An aetiological agent in Whipple's disease?
• Liver stiffness values in healthy subjects: Implications for clinical practice.
• Management of liver disease in Nigeria.
• Metabonomics in hepatic encephalopathy: lucidity emerging from confusion.
• Reassessment of BV causation.
• The role of mycoplasmas in pregnancy outcome.
• Transient elastography for the assessment of chronic liver disease: ready for the clinic?
• Transient elastography in acute hepatitis: All that's stiff is not fibrosis.
• Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions.